Drugs / R-5780
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06398418 | Aug 2025 → Apr 2027 expected | adenoma, basal cell carcinoma, melanoma, squamous cell carcinoma | Rise Therapeutics LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | Rise Therapeutics LLC | Regulatory Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer risetherapeutics.com ↗
The FDA's clearance for R-5780 is a testament to the innovation and dedication of our team at Rise Therapeutics driving novel immunotherapies forward into human proof-of-concept |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-22 | Rise Therapeutics LLC | Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion risetherapeutics.com ↗ |
| 2025-01-13 | Rise Therapeutics LLC | Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer risetherapeutics.com ↗ |
| 2021-08-31 | Rise Therapeutics LLC | Rise Therapeutics Announces Publication of a New Article Related to its R-5780 Program risetherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-5780 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06398418 ↗ |
| Route | Oral | “orally taken probiotic (R-5780)” NCT06398418 ↗ |